Details for Patent: 8,933,086

Title:	Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
Abstract:	The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):	Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Wilmington, DE), Fridman; Jordan S. (Newark, DE), Vaddi; Krishna (Kennett Square, PA)
Assignee:	Incyte Corporation (Wilmington, DE)
Filing Date:	Sep 20, 2013
Application Number:	14/033,039
Claims:	1. A method of treating pancreatic cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound that is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]prop- anenitrile, or a pharmaceutically acceptable salt thereof. 2. A method according to claim 1, wherein said compound is (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl- ]propanenitrile, or a pharmaceutically acceptable salt thereof. 3. A method according to claim 2, further comprising administering to said patient an additional therapeutic agent. 4. The method according to claim 3, wherein said additional therapeutic agent is a chemotherapeutic agent. 5. The method according to claim 4, wherein said method comprises administering said compound, or said salt, and said chemotherapeutic agent simultaneously to the patient. 6. The method according to claim 4, wherein said method comprises administering said compound, or said salt, and said chemotherapeutic agent sequentially to said patient. 7. The method according to claim 2, wherein about 5 to about 1000 mg of said compound or said salt is administered to said patient.